RxDoctor Payments Data

Jessica Schultz, MD

Advanced Heart Failure and Transplant Cardiology · Minneapolis, MNNPI 1124405543

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 86.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $4,254 and has fallen 80.9% since, to $813 in 2025.

$8,311in general payments, 2019–2025

Across 38 payments — averaging $218.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Medtronic$918
  • Impulse Dynamics (USA) Inc.$108
  • AstraZeneca$44
  • Angiodynamics, Inc.$17

What the payments were for

  • Speaking & faculty fees$3,61343%
  • Grants$91811%
  • Travel & lodging$1,67920%
  • Food & beverage$2,10225%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,311 in reported general payments places this provider in the 75th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.

See all advanced heart failure and transplant cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$88,558
Medicare patients
241
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan118$165,892
EliquisApixaban73$77,969
JardianceEmpagliflozin49$66,342
FarxigaDapagliflozin Propanediol19$25,014
Everolimus13$22,207
XareltoRivaroxaban14$13,794
Sirolimus17$10,393
PrografTacrolimus23$7,139
Tacrolimus55$7,092
Mycophenolate Mofetil77$6,569
Metoprolol Succinate144$3,521
Torsemide64$1,960
Potassium Chloride42$1,924
Rosuvastatin Calcium140$1,880
Losartan Potassium140$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$44$25,01419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 32 advanced heart failure and transplant cardiology providers in Minnesota.

Other advanced heart failure and transplant cardiology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →